Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)
NCT ID: NCT02219633
Last Updated: 2025-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2014-07-31
2015-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)
NCT02496546
Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream
NCT01850849
LEO19123 Cream in the Treatment of Atopic Dermatitis
NCT00392067
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
NCT04922021
A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis
NCT01005823
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LEO 39652 cream
Topical application
LEO 39652 cream
Applied for 21 days
LEO 39652 cream vehicle
Topical application
LEO 39652 cream
Applied for 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LEO 39652 cream
Applied for 21 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Two symmetrical and comparable Entire Treatment Areas, on the same body region (left and right part)
* Subjects must be in good health
* Female subjects of childbearing potential and male subjects must be willing to consent to using high effective methods of contraception
Exclusion Criteria
* Dark-skinned persons (i.e. skin type IV to VI according to Fitzpatrick classification system) whose skin colour prevents reliable clinical assessments
* Any permanent (or transient within 28 days prior to dosing) disease (in particular cardiac disease such as heart failure or history of myocardial infarction) that may interfere with the subjects safe participation in the trial, with the subjects ability to participate in the trial or with the clinical assessments
* Subjects with congenital or acquired immunodeficiencies or in subjects on therapy that causes immunosuppression
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lydia Graßhoff, MD
Role: PRINCIPAL_INVESTIGATOR
Proinnovera GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
proinnovera GmbH, Center of Dermatology Excellence
Münster, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at LEO Pharma
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-000849-80
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
LP0083-1085
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.